OncLive TV

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses ongoing work in mantle cell lymphoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of immunotherapy in oligometastatic non–small cell lung cancer.

Wells A. Messersmith, MD, co-director of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses molecular markers to be aware of in patients with colorectal cancer (CRC).

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses therapies for patients with penta-refractory multiple myeloma.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1–low bladder cancer.

Yee Chung Cheng, MD, associate professor of medicine, Medical College of Wisconsin, discusses the role of T-DM1 in patients with HER2-positive breast cancer.

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses targets under evaluation in mantle cell lymphoma.

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses the benefit of PD-L1 inhibition in small cell lung cancer.

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses caveats of the avelumab plus axitinib combination in frontline advanced renal cell carcinoma.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the benefit of alectinib in the treatment of patients with ALK-positive non–small cell lung cancer.

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

John Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses challenges with biosimilars in oncology.

Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, institute physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the immunogenicity of glioblastoma.

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses applications of immunotherapy in melanoma.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the outlook for patients with oncogene-driven non–small cell lung cancer.

Francisco J. Esteva, MD, PhD, director, Breast Medical Oncology, professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the prevalence of precision medicine in the treatment of patients with breast cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses sequencing beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses research with immune therapy in prostate cancer.

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses the watch-and-wait approach in mantle cell lymphoma.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the treatment era before immunotherapy in head and neck cancer.

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the safety profile of dostarlimab (TSR-042) in patients with endometrial cancer.

Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the future of immunotherapy in bladder cancer.